Compare ISPO & NRXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | ISPO | NRXS |
|---|---|---|
| Founded | 2010 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.9M | 25.8M |
| IPO Year | N/A | 2023 |
| Metric | ISPO | NRXS |
|---|---|---|
| Price | $4.15 | $3.90 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | 562.2K | ★ 854.7K |
| Earning Date | 11-04-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $247,652,000.00 | $3,362,320.00 |
| Revenue This Year | N/A | $31.05 |
| Revenue Next Year | $156.55 | $137.61 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 36.89 |
| 52 Week Low | $2.19 | $1.33 |
| 52 Week High | $7.17 | $6.20 |
| Indicator | ISPO | NRXS |
|---|---|---|
| Relative Strength Index (RSI) | 84.14 | 69.03 |
| Support Level | $4.14 | $2.63 |
| Resistance Level | $4.20 | $4.25 |
| Average True Range (ATR) | 0.04 | 0.34 |
| MACD | 0.12 | 0.13 |
| Stochastic Oscillator | 97.22 | 78.57 |
Inspirato Inc is a private, luxury hospitality club that provides its members with access to an exclusive portfolio of high-end vacation homes, luxury hotels, and curated travel experiences worldwide. The club offers personalized service, dedicated trip planning, and seamless access to exceptional properties through its innovative model designed to ensure the service, certainty and value that discerning customers demand. The Inspirato portfolio of curated luxury vacation options includes approximately 350 private luxury vacation homes and accommodations at over 220 luxury hotel and resort partners in over 180 destinations around the world.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).